Table 1 Neuropathological data for cases used in this study
Sample | Neuropath | Thal | Braak | CERAD | APOE | Sex | Age | PMI | MMSE score | Lewy body pathology | LATE-NC |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Low AD | 1 | I | None | 3/3 | F | 72 | 144 | NA | No | No |
2 | Low AD | 1 | I | None | 3/3 | F | 65 | 15 | NA | No | No |
3 | Low AD | 1 | III | None | 3/4 | F | 79 | 72 | NA | No | No |
4 | Low AD | 1 | III | None | 3/3 | F | 92 | 8 | NA | No | No |
5 | Low AD | 1 | IV | None | 2/3 | F | 74 | 7.5 | NA | No | No |
6 | Low AD | 2 | II | None | 3/4 | F | 63 | 168 | NA | No | No |
7 | Low AD | 2 | III | None | 3/4 | F | 82 | 5 | NA | No | No |
8 | Low AD | 3 | II | Sparse | 3/3 | F | 96 | 16 | NA | No | No |
9 | Low AD | 4 | II | Sparse | 2/3 | F | 77 | 12 | 30/30 | No | No |
10 | Low AD | 4 | 0 | None | 3/4 | F | 82 | 22 | 20/30 | No | No |
11 | Low AD | 4 | I | None | 3/3 | F | 66 | 72 | NA | No | No |
12 | Low AD | 1 | I | None | 2/3 | M | 68 | 48 | NA | No | No |
13 | Low AD | 1 | II | None | 3/3 | M | 89 | 28 | NA | No | No |
14 | Low AD | 3 | II | mild | 3/3 | M | 91 | 72 | NA | No | No |
15 | Low AD | 3 | II | Sparse | 3/3 | M | 81 | 144 | NA | No | No |
16 | Low AD | 1 | II | None | 3/3 | M | 90 | 14 | NA | No | No |
17 | Low AD | 1 | II | None | 3/3 | M | 88 | 4 | 19/30 | No | No |
18 | Low AD | 3 | II | Sparse | 3/3 | M | 79 | 34 | unspecific dementia | No | No |
19 | Intermediate AD | 4 | III | Moderate | 3/3 | F | 83 | 192 | NA | No | No |
20 | Intermediate AD | 5 | IV | Frequent | 3/3 | F | 100 | 18 | NA | No | No |
22 | Intermediate AD | 3 | II | Sparse | 3/3 | F | 79 | ? | NA | No | No |
23 | Intermediate AD | 5 | IV | Frequent | 3/3 | F | 93 | 18 | NA | No | stage 2 |
24 | Intermediate AD | 4 | IV | Frequent | 3/3 | F | 89 | 8 | 24/30 | No | No |
25 | Intermediate AD | 4 | III | moderate | 3/3 | F | 106 | 4 | NA | No | No |
26 | Intermediate AD | 3 | V | Frequent | 3/3 | F | 83 | 27 | NA | No | No |
27 | Intermediate AD | 3 | IV | moderate | 3/4 | F | 74 | 192 | NA | No | No |
28 | Intermediate AD | 4 | V | moderate | 3/4 | F | 99 | 8 | NA | No | No |
29 | Intermediate AD | 4 | IV | Frequent | 3/3 | F | 90 | 19 | MOCA- 22/30 | No | No |
30 | Intermediate AD | 5 | IV | Frequent | 3/3 | M | 72 | 72 | NA | No | No |
31 | Intermediate AD | 5 | IV | moderate | 3/3 | M | 86 | 48 | NA | No | No |
33 | Intermediate AD | 5 | III | sparse | 2/4 | M | 78 | 4 | MOCA- 11/29 | No | No |
34 | Intermediate AD | 4 | III | sparse | 3/4 | M | 86 | 12 | NA | No | No |
35 | Intermediate AD | 4 | III | moderate | 3/3 | M | 72 | 17 | 30/30 | No | No |
36 | Intermediate AD | 5 | IV | Frequent | 3/4 | M | 90 | 7 | NA | No | No |
37 | Intermediate AD | 3 | VI | moderate | 3/3 | M | 82 | 13 | 1/30 | No | No |
38 | Intermediate AD | 5 | III | moderate | 3/3 | M | 83 | 22 | NA | No | No |
39 | Intermediate AD | 5 | IV | moderate | 3/3 | M | 78 | 10 | NA | No | stage 2 |
40 | Intermediate AD | 3 | IV | sparse | 3/3 | M | 73 | 8 | NA | No | stage 2 |
21 | High AD Pure | 5 | VI | moderate | 2/3 | F | 68 | 9 | NA | No | No |
32 | High AD Pure | 5 | VI | moderate | 3/3 | M | 73 | 7 | NA | No | No |
41 | High AD Pure | 5 | V | Frequent | 2/4 | F | 97 | 10 | NA | No | No |
42 | High AD Pure | 5 | VI | Frequent | 3/3 | F | 63 | 10 | NA | No | No |
43 | High AD Pure | 5 | V | Frequent | 3/3 | F | 83 | 9 | NA | No | No |
44 | High AD Pure | 5 | V | Frequent | 3/3 | F | 78 | 5 | NA | No | No |
45 | High AD Pure | 5 | V | Frequent | 3/3 | F | 64 | 12 | NA | No | No |
46 | High AD Pure | 5 | VI | Frequent | 3/3 | F | 76 | 3.5 | dementia reported | No | No |
47 | High AD Pure | 5 | VI | Frequent | 3/3 | F | 80 | 19 | NA | No | No |
48 | High AD Pure | 4 | V | Frequent | 3/4 | F | 85 | 18 | 23/30 | No | No |
49 | High AD Pure | 5 | V | Frequent | 3/4 | F | 72 | 12 | NA | No | No |
50 | High AD Pure | 5 | V | Frequent | 3/4 | F | 86 | 14 | 13/30 | No | No |
62 | High AD Pure | 4 | V | Frequent | 3/4 | M | 84 | 16 | 9/30 | No | No |
63 | High AD Pure | 5 | V | Frequent | 3/4 | M | 78 | 20 | 15/30 | No | No |
64 | High AD Pure | 5 | V | Frequent | 3/4 | M | 74 | 12 | CDR 0 | No | No |
65 | High AD Pure | 5 | V | Frequent | 3/3 | M | 95 | 5 | NA | No | No |
66 | High AD Pure | 4 | V | Frequent | 3/4 | M | 77 | 5 | 21/30 | No | No |
67 | High AD Pure | 5 | VI | Frequent | 3/3 | M | 66 | 5 | NA | No | No |
68 | High AD Pure | 5 | VI | Frequent | 3/3 | M | 79 | 21 | 16/30 | No | No |
69 | High AD Pure | 5 | VI | Frequent | 3/4 | M | 63 | 2 | NA | No | No |
70 | High AD Pure | 5 | VI | Frequent | 3/3 | M | 83 | 7 | NA | No | No |
71 | High AD Pure | 5 | VI | Frequent | 3/4 | M | 59 | 7 | 14/30 | No | No |
72 | High AD Pure | 5 | VI | Frequent | 4/4 | M | 70 | 8 | NA | No | No |
51 | High AD mixed | 5 | VI | Frequent | 3/4 | F | 84 | 72 | NA | diffuse neocortical | No |
52 | High AD mixed | 5 | V | Frequent | 3/4 | F | 83 | 6 | NA | diffuse neocortical | No |
53 | High AD mixed | 5 | VI | Frequent | 4/4 | F | 75 | NA | dementia reported | diffuse neocortical | stage 2 |
54 | High AD mixed | 4 | V | Frequent | 3/4 | F | 76 | 20 | dementia reported | diffuse neocortical | stage 3 |
55 | High AD mixed | 5 | V | Frequent | 3/3 | F | 63 | 12 | 26/30 | diffuse neocortical | stage 3 |
56 | High AD mixed | 5 | V | Frequent | 2/3 | F | 98 | 9 | 20/30 | diffuse neocortical | stage 3 |
57 | High AD mixed | 5 | VI | Frequent | 4/4 | F | 75 | 8 | 22/30 | amygdala-predominant | stage 1 |
58 | High AD mixed | 5 | VI | Frequent | 3/4 | F | 83 | 11 | 23/30 | amygdala-predominant | no |
59 | High AD mixed | 5 | V | Frequent | 3/3 | F | 88 | 4 | 2/30 | amygdala-predominant | no |
60 | High AD mixed | 5 | VI | Frequent | 4/4 | F | 76 | 3 | 14/30 | limbic-transitional | stage 3 |
61 | High AD mixed | 5 | V | Frequent | 3/3 | F | 78 | 12 | NA | limbic-transitional | stage 2 |
73 | High AD mixed | 5 | V | Frequent | 3/4 | M | 80 | 21 | NA | diffuse neocortical | stage 2 |
74 | High AD mixed | 5 | VI | Frequent | 3/3 | M | 62 | 5 | NA | diffuse neocortical | stage 2 |
75 | High AD mixed | 5 | VI | Frequent | 3/4 | M | 78 | 22 | NA | diffuse neocortical | No |
76 | High AD mixed | 5 | V | Frequent | 3/3 | M | 64 | 3 | 7/30 | amygdala-predominant | No |
77 | High AD mixed | 5 | VI | Frequent | 3/3 | M | 70 | 4 | 13/30 | amygdala-predominant | stage 2 |
78 | High AD mixed | 5 | VI | Frequent | 3/3 | M | 87 | 9 | NA | diffuse neocortical | No |
79 | High AD mixed | 5 | V | Frequent | 3/3 | M | 94 | 144 | NA | limbic-transitional | No |
80 | High AD mixed | 5 | VI | Frequent | 4/4 | M | 91 | 14.25 | NA | diffuse neocortical | stage 1 |
81 | High AD mixed | 5 | V | Frequent | 3/3 | M | 85 | 25 | NA | amygdala-predominant | No |
82 | High AD mixed | 5 | V | Frequent | 3/3 | M | 79 | 14 | 6/30 | amygdala-predominant | stage 1 |
83 | High AD mixed | 5 | VI | Frequent | 3/3 | M | 83 | 11 | NA | amygdala-predominant | stage 1 |